Other News

Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022

Co-registration of real-time intravascular ultrasound and/or iFR physiological assessment data onto motion-compensated angiograms aids percutaneous coronary intervention (PCI) procedure planning, quantitative lesion measurement, stent choice and sizing, and therapy assessment Reduced need for contrast media enables broader access to PCI for patients at risk of acute kidney injury Ultra-low contrast […]

New release of Philips EchoNavigator helps interventional teams treat structural heart disease with greater ease and efficiency

EchoNavigator 4.0 empowers heart teams with greater control of live fusion imaging plus new anatomical modeling and transseptal puncture guidance during minimally-invasive procedures Seamless integration and communication between Philips Ultrasound System – EPIQ CVxi – and Philips Image Guided Therapy System – Azurion – supports efficient fusion-imaging workflow for minimally-invasive treatment of structural heart disease Amsterdam, the Netherlands […]

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

VANCOUVER and MINNEAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (the “Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under […]

scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application

PDUFA action date set for October 8, 2022 Company preparing for Q4 commercial launch, if approved BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient […]

scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved Ended Q1 with cash, cash equivalents, restricted cash and investments of $65.6 million BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals […]

FUJIFILM VisualSonics Launches the New Multi-modal Vevo F2 Imaging Platform for Preclinical Ultrasound

First to feature the full range of ultra-high to low frequency ultrasound capability TORONTO, May 16, 2022 (GLOBE NEWSWIRE) — FUJIFILM VisualSonics Inc., a world leader in ultra-high frequency ultrasound and photoacoustic imaging systems, has announced the launch of Vevo® F2, the world’s first ultra-high to low frequency (71MHz-1MHz) ultrasound and […]

Vesalio Announces Completion of Enrollment in it’s FDA Enabling Stroke Study

Nashville, TN (May 11, 2022) – Vesalio is excited to announce the completion of patient enrollment for the CLEAR1 FDA IDE study utilizing the NeVa™ thrombectomy platform. This is an important milestone for Vesalio to complete for entering the U.S. neurovascular market to treat patients suffering from acute ischemic stroke (AIS).  AIS […]

Medtronic receives FDA approval for latest generation drug-eluting coronary stent system

The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN, May 13, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx […]

Humacyte First Quarter 2022 Financial Results and Business Update

— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries — — Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer —  — Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data — — Conference […]

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

Conference call scheduled for 8:30 a.m. ET today MIAMI, May 13, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter […]